E
Elena Matsa
Researcher at Stanford University
Publications - 30
Citations - 4157
Elena Matsa is an academic researcher from Stanford University. The author has contributed to research in topics: Induced pluripotent stem cell & Embryonic stem cell. The author has an hindex of 24, co-authored 29 publications receiving 3437 citations. Previous affiliations of Elena Matsa include Cardiovascular Institute of the South & University of Nottingham.
Papers
More filters
Journal ArticleDOI
Chemically defined generation of human cardiomyocytes
Paul W. Burridge,Elena Matsa,Praveen K. Shukla,Ziliang C Lin,Jared M. Churko,Antje D. Ebert,Feng Lan,Sebastian Diecke,Bruno C. Huber,Nicholas M. Mordwinkin,Jordan R. Plews,Oscar J. Abilez,Bianxiao Cui,Joseph D. Gold,Joseph C. Wu +14 more
TL;DR: This work systematically developed an optimized cardiac differentiation strategy, using a chemically defined medium consisting of just three components: the basal medium RPMI 1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin, which was effective in 11 hiPSC lines tested.
Journal ArticleDOI
Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Paul W. Burridge,Yong Fuga Li,Elena Matsa,Haodi Wu,Sang-Ging Ong,Arun Sharma,Alexandra Holmström,Alex C.Y. Chang,Michael Coronado,Antje D. Ebert,Joshua W. Knowles,Melinda L. Telli,Ronald M. Witteles,Helen M. Blau,Daniel Bernstein,Russ B. Altman,Joseph C. Wu +16 more
TL;DR: It is demonstrated that patient-specific human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) can recapitulate the predilection to doxorubicin-induced cardiotoxicity of individual patients at the cellular level.
Journal ArticleDOI
Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation
Elena Matsa,Divya Rajamohan,Emily Dick,Lorraine E. Young,Ian R. Mellor,Andrew Staniforth,Chris Denning +6 more
TL;DR: It is demonstrated that patient LQT2–hiPSC cardiomyocytes respond appropriately to clinically relevant pharmacology and will be a valuable human in vitro model for testing experimental drug combinations.
Journal ArticleDOI
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Arun Sharma,Paul W. Burridge,Paul W. Burridge,Wesley L. McKeithan,Wesley L. McKeithan,Ricardo Serrano,Praveen K. Shukla,Nazish Sayed,Jared M. Churko,Tomoya Kitani,Haodi Wu,Alexandra Holmström,Elena Matsa,Yuan Zhang,Anusha Kumar,Alice C. Fan,Juan C. del Álamo,Sean M. Wu,Javid Moslehi,Mark Mercola,Mark Mercola,Joseph C. Wu +21 more
TL;DR: In this article, the authors used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in Cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling.
Journal ArticleDOI
Human Stem Cells for Modeling Heart Disease and for Drug Discovery
TL;DR: This Perspective highlights recent research progress in the use of stem cells and progenitor cells for disease modeling, drug discovery, and cardiac regeneration.